Radiation Detection in Nuclear Medicine — MCQs
99m Technetium labeled RBC scintigraphy is PRIMARILY used in the diagnosis of
Which radioisotope is commonly used in teletherapy?
Radiation Dose Monitoring in Occupational Workers is done by
Hot spot in heart is seen in which scan
A dense nephrogram is obtained by
The T1/2 of Iodine-131 is:
Which of the following agents is used to measure Glomerular Filtration Rate (GFR)?
Which artificial radioisotopes are used in nuclear medicine?
Which radiopharmaceutical is used for a liver scan?
What is the investigation of choice for whole-body imaging in metastasis?
Radiation Detection in Nuclear Medicine Indian Medical PG Practice Questions and MCQs
Question 1: 99m Technetium labeled RBC scintigraphy is PRIMARILY used in the diagnosis of
- A. Hepatoma
- B. Left ventricular function wall motion
- C. Hepatic hemangioma
- D. GI Bleeding (Correct Answer)
Explanation: ***GI Bleeding*** - Technetium-99m labeled RBC scintigraphy (**<sup>99m</sup>Tc-RBC scan**) is highly sensitive for detecting **active gastrointestinal bleeding**, especially slow or intermittent bleeding. - The labeled red blood cells extravasate at the site of bleeding, accumulating and outlining the bleeding focus over time. *Hepatoma* - **Hepatoma** (hepatocellular carcinoma) is primarily diagnosed using imaging modalities like **CT, MRI**, and **ultrasound**, often with contrast enhancement. - While nuclear medicine scans like **FDG-PET** can be used in some cases for staging or assessing viability, <sup>99m</sup>Tc-RBC scans are not a primary diagnostic tool for hepatoma. *Left ventricular function wall motion* - **Left ventricular function** and **wall motion abnormalities** are typically assessed using **echocardiography**, cardiac **MRI**, or **nuclear cardiology studies** like **SPECT** or **PET** using tracers that localize in the myocardium (e.g., <sup>99m</sup>Tc-Sestamibi or Thallium-201). - <sup>99m</sup>Tc-RBC scans are sometimes used for **gated blood pool scans** to assess global ejection fraction, but not directly for wall motion analysis in the same way as other dedicated cardiac modalities. *Hepatic hemangioma* - **Hepatic hemangiomas** can be characterized by **<sup>99m</sup>Tc-RBC scintigraphy**, which shows **early photopenia** followed by **delayed fill-in and retention** of the tracer due to the characteristic slow blood flow within these benign vascular tumors. - While it can be used for confirmation, it's not the most commonly used primary diagnostic tool (which is often **ultrasound** or **MRI** with specific contrast patterns), and GI bleeding is a more direct application where the scan detects extravasation rather than vascular pooling.
Question 2: Which radioisotope is commonly used in teletherapy?
- A. Ra-226
- B. Cs-137
- C. Co-60 (Correct Answer)
- D. Ir-192
Explanation: ***Co-60*** - **Cobalt-60** is a widely used radioisotope in teletherapy (external beam radiotherapy) due to its high-energy gamma emissions (1.17 and 1.33 MeV). - Its relatively long half-life of **5.27 years** makes it practical for sustained clinical use in **teletherapy units**. *Ra-226* - **Radium-226** was historically used in brachytherapy but has largely been replaced due to its alpha emissions, which are difficult to shield, and its long-lived radioactive decay products. - Its use for teletherapy is **not common** because of these safety concerns and the availability of more suitable isotopes. *Cs-137* - **Cesium-137** is primarily used in **brachytherapy** and some low-dose rate teletherapy machines for specific applications, but not as commonly as Co-60 for general teletherapy. - Its lower gamma energy (0.662 MeV) and shorter half-life than Co-60 (30.17 years) make it less ideal for the widespread **deep penetration** required in many teletherapy treatments. *Ir-192* - **Iridium-192** is predominantly used in **high-dose-rate (HDR) brachytherapy** for temporary implants, delivering radiation over short periods. - Its relatively short half-life of **73.8 days** and lower average gamma energy make it unsuitable for typical long-term teletherapy external beam applications.
Question 3: Radiation Dose Monitoring in Occupational Workers is done by
- A. TLD Badge (Correct Answer)
- B. Collimators
- C. Grid
- D. Linear Accelerator
Explanation: ***TLD Badge (used for monitoring radiation exposure)*** - **Thermoluminescent Dosimeter (TLD) badges** are widely used for monitoring an individual's exposure to ionizing radiation over time. - They work by storing energy from radiation exposure and releasing it as **light when heated**, which is then measured to calculate the accumulated dose. *Collimators (used to shape radiation beams)* - **Collimators** are devices used in radiation therapy and diagnostic imaging to **restrict and shape the radiation beam**, ensuring it only targets the intended area. - They do not measure or monitor the dose received by an individual, but rather **control the spatial distribution** of the radiation. *Grid (used to reduce scatter in imaging)* - An **anti-scatter grid** is placed between the patient and the image receptor in radiography to **absorb scattered radiation**, which degrades image quality. - While essential for image quality, grids do not directly measure or monitor the radiation dose received by an occupational worker. *Linear Accelerator (used for delivering radiation therapy)* - A **linear accelerator (linac)** is a machine used to deliver **external beam radiation treatment** for cancer. - It generates high-energy X-rays or electrons, but it is a **source of radiation** for treatment, not a device for monitoring occupational exposure.
Question 4: Hot spot in heart is seen in which scan
- A. Thallium
- B. Gallium
- C. Albumin labelled
- D. Tc pyrophosphate scan (Correct Answer)
Explanation: ***Tc pyrophosphate scan*** - A **technetium-99m pyrophosphate (Tc-PYP) scan** demonstrates a "hot spot" in the heart in cases of **acute myocardial infarction** due to the tracer binding to calcium deposits in necrotic cardiomyocytes. - This hot spot indicates recent myocardial damage and is particularly useful in diagnosing **amyloidosis** (specifically transthyretin cardiac amyloidosis) where the tracer binds to amyloid fibrils. *Thallium* - **Thallium-201** is used in myocardial perfusion imaging to assess areas of reduced blood flow or infarction, creating a "cold spot" (decreased uptake). - It acts as a potassium analog and is taken up by viable myocardial cells, thus areas of ischemia or necrosis appear as defects rather than hot spots. *Gallium* - **Gallium-67** scans are primarily used to detect infection and inflammation, as well as certain tumors. - While it can accumulate in areas of inflammation in the heart (e.g., myocarditis), it does not create a characteristic "hot spot" associated with acute myocardial infarction. *Albumin labelled* - **Technetium-99m labeled albumin** (e.g., Technetium-99m macroaggregated albumin, MAA) is typically used for lung perfusion scans to diagnose pulmonary embolism or for gastrointestinal bleeding studies. - It is not used for direct assessment of myocardial damage or to create a "hot spot" in the heart for ischemic events.
Question 5: A dense nephrogram is obtained by
- A. Dehydrating the patient
- B. Rapid (Bolus) injection of dye (Correct Answer)
- C. Using non ionic media
- D. Increasing the dose of contrast media
Explanation: ***Rapid (Bolus) injection of dye*** - A **rapid bolus injection** of contrast material ensures a high concentration reaches the kidneys simultaneously, leading to optimal opacification and a **dense nephrogram**. - This method allows for the collection of a **large bolus of undiluted contrast** in the renal vessels and parenchyma, improving visualization of the renal parenchyma during the nephrographic phase. - The dense nephrogram phase occurs when contrast is within the renal tubules and interstitium, producing uniform opacification. *Dehydrating the patient* - **Dehydration** would concentrate the urine in the collecting system, but it does not directly contribute to the **dense nephrogram** appearance of the renal parenchyma. - While dehydration may improve visualization of the pelvicalyceal system on delayed images, it can increase the risk of **contrast-induced nephropathy**. *Using non ionic media* - **Non-ionic contrast media** are associated with fewer adverse reactions and greater patient safety compared to ionic media due to their lower osmolality. - However, the type of contrast media (ionic vs. non-ionic) does not primarily determine the **density of the nephrogram** itself, but rather patient tolerability and safety profile. *Increasing the dose of contrast media* - While increasing the dose might provide more contrast overall, it does not guarantee a **dense nephrogram**, which requires a high concentration of contrast to be present acutely in the renal parenchyma. - A dense nephrogram is better achieved by **rapid bolus injection technique** rather than simply increasing the total dose. - Excessive contrast increases the risk of **adverse reactions** and contrast-induced nephropathy without necessarily improving nephrographic density proportionally.
Question 6: The T1/2 of Iodine-131 is:
- A. 8 days (Correct Answer)
- B. 12 hours
- C. 13 days
- D. 2 days
Explanation: ***8 days*** - Iodine-131 (¹³¹I) has a relatively short half-life of **8.02 days**, making it suitable for diagnostic and therapeutic uses with a controlled radiation exposure window. - This **half-life** allows for effective patient monitoring and targeted treatment while minimizing long-term radiation risks. *12 hours* - This is an incorrect value; 12 hours is a significantly shorter half-life than that of **Iodine-131**. - Other isotopes, such as **Iodine-123**, have a half-life of 13.2 hours, which is closer to this value but still distinct from **Iodine-131**. *13 days* - This value is close but incorrect; the correct half-life for **Iodine-131** is approximately **8 days**. - A 13-day half-life would imply a longer period of radioactivity, altering its clinical applications. *2 days* - This is an incorrect half-life for **Iodine-131**, which has a significantly longer half-life of approximately 8 days. - A 2-day half-life would mean the isotope decays much faster than it actually does.
Question 7: Which of the following agents is used to measure Glomerular Filtration Rate (GFR)?
- A. Iodohippurate
- B. Tc99m-DTPA (Correct Answer)
- C. Tc99m-MAG3
- D. Tc99m-DMSA
Explanation: ***Tc99m-DTPA*** - Technetium-99m-Diethylenetriaminepentaacetic acid (**Tc99m-DTPA**) is a radiopharmaceutical that is cleared almost exclusively by **glomerular filtration** (~98%), making it the ideal agent for measuring GFR. - Its **renal clearance rate** directly correlates with the GFR, providing an accurate, non-invasive assessment of kidney function. - Used for dynamic renal scintigraphy to calculate GFR quantitatively. *Iodohippurate* - **Iodohippurate (OIH)** is primarily cleared by **tubular secretion** (~80%), similar to Para-aminohippuric acid (PAH). - It is used to measure **renal plasma flow (RPF)** or **effective renal plasma flow (ERPF)**, not GFR. - Not suitable for GFR measurement due to its tubular handling mechanism. *Tc99m-MAG3* - Technetium-99m-Mercaptoacetyltriglycine (**Tc99m-MAG3**) is predominantly handled by **tubular secretion** (~90%). - Used to assess **effective renal plasma flow (ERPF)** and is preferred in patients with impaired renal function due to its high extraction efficiency. - Has largely replaced OIH in clinical practice but does not measure GFR. *Tc99m-DMSA* - Technetium-99m-Dimercaptosuccinic acid (**Tc99m-DMSA**) binds to the **proximal tubular cells** in the renal cortex (~40-50% accumulation). - Used for **static renal cortical scintigraphy** to evaluate renal morphology, differential renal function, and detect cortical scarring. - Not cleared by glomerular filtration and unsuitable for GFR measurement.
Question 8: Which artificial radioisotopes are used in nuclear medicine?
- A. Radium
- B. Uranium
- C. Plutonium (Correct Answer)
- D. Iridium
Explanation: ### Explanation **Correct Answer: C. Plutonium** In nuclear medicine, radioisotopes are categorized as either **natural** (found in nature) or **artificial** (man-made via nuclear reactors or cyclotrons). **Plutonium (specifically Pu-238)** is an artificial radioisotope produced in nuclear reactors. While not used as a diagnostic tracer or therapeutic agent for internal administration, it has a significant historical and niche clinical application as a power source for **Radioisotope Thermoelectric Generators (RTGs)** in long-lived **cardiac pacemakers**. Its high energy density and long half-life made it ideal for devices requiring decades of operation without battery replacement. **Analysis of Incorrect Options:** * **A. Radium:** This is a **naturally occurring** radioactive metal found in uranium ores. While Radium-223 is used in treating bone metastases (Xofigo), the element itself is classified as natural. * **B. Uranium:** This is a **naturally occurring** heavy metal. It is the raw material used to produce artificial isotopes but is not used directly in clinical nuclear medicine. * **C. Iridium:** While Iridium-192 is used in Brachytherapy, it is generally classified as a transition metal used in "sealed sources" for radiotherapy rather than being the classic example of an "artificial radioisotope" in the context of general nuclear medicine tracers (like Technetium-99m). However, in the context of this specific question, Plutonium is the most distinct "artificial/man-made" element. **High-Yield Clinical Pearls for NEET-PG:** * **Technetium-99m (Tc-99m):** The most commonly used artificial radioisotope in diagnostic nuclear medicine (produced in a Mo-99/Tc-99m generator). * **Cyclotron-produced isotopes:** Include F-18 (used in PET scans), I-123, and Thallium-201. * **Reactor-produced isotopes:** Include I-131, Mo-99, and Xenon-133. * **Therapeutic Alpha Emitter:** Radium-223 is the first alpha-emitting radiopharmaceutical approved to improve survival in castration-resistant prostate cancer with bone metastases.
Question 9: Which radiopharmaceutical is used for a liver scan?
- A. Tc-99m sulphur colloid (Correct Answer)
- B. Tc-99m mebrofenin
- C. Tc-99m MIBI
- D. Tc-99m DTPA
Explanation: **Explanation:** The correct answer is **Tc-99m sulphur colloid**. The underlying principle for a liver-spleen scan is the **phagocytic activity of the Reticuloendothelial System (RES)**. When Tc-99m sulphur colloid is injected intravenously, the particles (sized 0.1–1.0 μm) are cleared from the blood by Kupffer cells in the liver (80–90%), splenic macrophages (5–10%), and bone marrow. This scan is primarily used to evaluate functional liver anatomy and detect "cold nodules" (e.g., abscesses or tumors) or "hot spots" (e.g., Focal Nodular Hyperplasia). **Analysis of Incorrect Options:** * **Tc-99m Mebrofenin:** This is an IDA (Iminodiacetic acid) derivative used for **HIDA scans**. It evaluates the **hepatobiliary system** (hepatocyte uptake and biliary excretion) and is the gold standard for diagnosing Acute Cholecystitis. * **Tc-99m MIBI:** Primarily used for **Myocardial Perfusion Imaging** and Parathyroid imaging. It is taken up by mitochondria. * **Tc-99m DTPA:** A chelating agent cleared by glomerular filtration, used for **Renal Dynamic Scans** to assess GFR and obstructive uropathy. **High-Yield Clinical Pearls for NEET-PG:** 1. **Colloid Shift:** In portal hypertension or cirrhosis, there is decreased liver uptake and increased uptake in the spleen and bone marrow. 2. **Focal Nodular Hyperplasia (FNH):** This is the only liver lesion that typically appears "hot" or "isointense" on a sulphur colloid scan due to the presence of Kupffer cells. 3. **Hot Spot on Liver Scan:** Classically seen in **Superior Vena Cava (SVC) Obstruction** (due to collateral flow via the vein of Sappey).
Question 10: What is the investigation of choice for whole-body imaging in metastasis?
- A. Magnetic Resonance Imaging
- B. Radiography
- C. Bone scan (Correct Answer)
- D. CT Scan
Explanation: **Explanation:** **Bone Scan (Technetium-99m MDP)** is the investigation of choice for screening whole-body skeletal metastases because of its high sensitivity and ability to image the entire skeleton in a single session. It works on the principle of detecting increased osteoblastic activity (bone remodeling) at sites of tumor infiltration. Its primary advantage is the ability to detect "hot spots" weeks or months before structural changes become visible on conventional X-rays. **Why other options are incorrect:** * **Radiography (X-ray):** It has low sensitivity for early metastasis. A bone lesion only becomes visible on an X-ray after **30-50% of bone mineral density is lost**. It is, however, the best modality to confirm a finding seen on a bone scan. * **CT Scan:** While excellent for evaluating cortical bone and detailed anatomy, it is not practical for whole-body screening due to high radiation doses and lower sensitivity for early marrow-based lesions compared to nuclear imaging. * **MRI:** MRI is the most sensitive modality for detecting **bone marrow infiltration**. However, it is not typically the first-line "investigation of choice" for whole-body screening due to high costs, long scan times, and limited availability of whole-body MRI protocols. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Tc-99m MDP (Methylene Diphosphonate) adsorbs onto the **hydroxyapatite crystals** of the bone. * **The "Cold Scan" Exception:** Highly aggressive or purely osteolytic tumors (e.g., Multiple Myeloma, Renal Cell Carcinoma, or Thyroid Cancer) may show as "cold" or false-negative on a bone scan because they do not trigger an osteoblastic response. * **Flare Phenomenon:** An apparent increase in tracer uptake seen shortly after starting chemotherapy, which actually represents healing bone rather than disease progression. * **Superscan:** A bone scan showing intense, uniform skeletal uptake with **absent renal/bladder activity**, typically seen in diffuse metastatic prostate cancer or hyperparathyroidism.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free